Rosetta Genomics Receives New York State Clinical Laboratory Permit for Its First Generation microRNA Diagnostic Tests

First Generation miRview® Tests Now Available to Residents of All 50 U.S. States

REHOVOT, ISRAEL and PHILADELPHIA, PA–(Marketwire – January 3, 2011) – Rosetta Genomics, Ltd. (“Rosetta”) (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the New York State Department of Health (NYS DOH) has issued Rosetta Genomics a Clinical Laboratory Permit. The permit will enable patients and physicians residing in the State of New York to gain access to the Company’s miRview® mets, miRview® squamous, and miRview® meso tests. The Company is now working to gain NYS DOH approval for the first of its second generation tests — miRview® mets2. (read the entire release… )